PubRank

Rituximab in Active Ulcerative Colitis

Clinical Trial ID NCT00261118

PubWeight™ 2.68‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00261118

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 19.60
2 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 8.40
3 Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987 7.73
4 Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002 5.42
5 A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989 4.27
6 Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998 3.45
7 Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011 2.68
8 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001 2.59
9 An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002 2.54
10 Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994 2.48
11 Rituximab for idiopathic membranous nephropathy. Lancet 2002 2.03
12 Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001 2.01
13 Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999 1.90
14 Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002 1.74
15 Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002 1.48
16 Immunoregulation in the gut: success and failures in human disease. Gut 2002 1.25
17 Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002 1.09
18 Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut 1994 0.95
19 Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 2002 0.93
20 Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998 0.92
21 B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum 2002 0.88
22 Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology 2003 0.79
23 Restricted V(H) gene usage in lamina propria B cells producing anticolon antibody from patients with ulcerative colitis. Gastroenterology 2001 0.78
Next 100